Liver-targeted regenerative medicine

Naoya Kobayashi, Chen Yong, Noriaki Tanaka

Research output: Contribution to journalArticle

Abstract

Recently, much attention has been drawn to liver-targeted regenerative medicine for the treatment of liver failure. Researchers in various fields consider that the following cells can be used for such therapy: human embryonic stem (ES) cells, somatic stem cells, hepatic stem cells, small hepatocytes, bone marrow- and cord blood-derived hepatic progenitor cells, and human hepatocyte cell lines. The Cre/loxP-based reversible immortalization of human hepatocytes is also introduced in this review article. Here we describe the candidates that can contribute to hepatic regeneration. This reversible immortalization system allows us to establish a highly safe human hepatocyte line that is capable of differentiation at a lower cost and on a larger scale.

Original languageEnglish (US)
Pages (from-to)440-444
Number of pages5
JournalNippon Geka Gakkai zasshi
Volume105
Issue number8
StatePublished - 2004
Externally publishedYes

Fingerprint

Regenerative Medicine
Hepatocytes
Liver
Stem Cells
Adult Stem Cells
Liver Failure
Treatment Failure
Fetal Blood
Regeneration
Bone Marrow
Research Personnel
Costs and Cost Analysis
Cell Line

Cite this

Kobayashi, N., Yong, C., & Tanaka, N. (2004). Liver-targeted regenerative medicine. Nippon Geka Gakkai zasshi, 105(8), 440-444.

Liver-targeted regenerative medicine. / Kobayashi, Naoya; Yong, Chen; Tanaka, Noriaki.

In: Nippon Geka Gakkai zasshi, Vol. 105, No. 8, 2004, p. 440-444.

Research output: Contribution to journalArticle

Kobayashi, N, Yong, C & Tanaka, N 2004, 'Liver-targeted regenerative medicine', Nippon Geka Gakkai zasshi, vol. 105, no. 8, pp. 440-444.
Kobayashi N, Yong C, Tanaka N. Liver-targeted regenerative medicine. Nippon Geka Gakkai zasshi. 2004;105(8):440-444.
Kobayashi, Naoya ; Yong, Chen ; Tanaka, Noriaki. / Liver-targeted regenerative medicine. In: Nippon Geka Gakkai zasshi. 2004 ; Vol. 105, No. 8. pp. 440-444.
@article{a78dadde855e482095dc9f8ce8bb8dad,
title = "Liver-targeted regenerative medicine",
abstract = "Recently, much attention has been drawn to liver-targeted regenerative medicine for the treatment of liver failure. Researchers in various fields consider that the following cells can be used for such therapy: human embryonic stem (ES) cells, somatic stem cells, hepatic stem cells, small hepatocytes, bone marrow- and cord blood-derived hepatic progenitor cells, and human hepatocyte cell lines. The Cre/loxP-based reversible immortalization of human hepatocytes is also introduced in this review article. Here we describe the candidates that can contribute to hepatic regeneration. This reversible immortalization system allows us to establish a highly safe human hepatocyte line that is capable of differentiation at a lower cost and on a larger scale.",
author = "Naoya Kobayashi and Chen Yong and Noriaki Tanaka",
year = "2004",
language = "English (US)",
volume = "105",
pages = "440--444",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "8",

}

TY - JOUR

T1 - Liver-targeted regenerative medicine

AU - Kobayashi, Naoya

AU - Yong, Chen

AU - Tanaka, Noriaki

PY - 2004

Y1 - 2004

N2 - Recently, much attention has been drawn to liver-targeted regenerative medicine for the treatment of liver failure. Researchers in various fields consider that the following cells can be used for such therapy: human embryonic stem (ES) cells, somatic stem cells, hepatic stem cells, small hepatocytes, bone marrow- and cord blood-derived hepatic progenitor cells, and human hepatocyte cell lines. The Cre/loxP-based reversible immortalization of human hepatocytes is also introduced in this review article. Here we describe the candidates that can contribute to hepatic regeneration. This reversible immortalization system allows us to establish a highly safe human hepatocyte line that is capable of differentiation at a lower cost and on a larger scale.

AB - Recently, much attention has been drawn to liver-targeted regenerative medicine for the treatment of liver failure. Researchers in various fields consider that the following cells can be used for such therapy: human embryonic stem (ES) cells, somatic stem cells, hepatic stem cells, small hepatocytes, bone marrow- and cord blood-derived hepatic progenitor cells, and human hepatocyte cell lines. The Cre/loxP-based reversible immortalization of human hepatocytes is also introduced in this review article. Here we describe the candidates that can contribute to hepatic regeneration. This reversible immortalization system allows us to establish a highly safe human hepatocyte line that is capable of differentiation at a lower cost and on a larger scale.

UR - http://www.scopus.com/inward/record.url?scp=7044227794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044227794&partnerID=8YFLogxK

M3 - Article

VL - 105

SP - 440

EP - 444

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 8

ER -